Bleyer Anthony J, Sedor John R, Freedman Barry I, O'Brien Alicia, Russell Gregory B, Graley Joni, Schelling Jeffrey R
Section on Nephrology, Wake Forest University School of Medicine, Winston Salem, NC 27106, USA.
Am J Kidney Dis. 2008 Jan;51(1):29-37. doi: 10.1053/j.ajkd.2007.10.029.
Diabetic siblings of patients with treated kidney failure from diabetic kidney disease are at a 5-fold increased risk of future kidney failure. The objective of this study is to define risk factors for kidney disease, clinical features, and treatment patterns in diabetic siblings of patients with diabetes with diabetic kidney disease.
Cross-sectional analysis using data collected from diabetic siblings of patients with diabetic kidney disease.
SETTING & PARTICIPANTS: 295 diabetic siblings with mean diabetes duration of 15 years from within a 400-mile radius of Cleveland, OH, or Winston-Salem, NC.
Demographic data, diabetes duration, blood pressure (BP), access to health care, and diabetes control.
Albuminuria (defined as urinary albumin-creatinine ratio >or= 30 mg/g, with microalbuminuria with albumin of 30 to 300 mg/g and macroalbuminuria with albumin > 300 mg/g), renal function.
BP, urinary albumin-creatinine ratio, serum creatinine, glycosylated hemoglobin (HbA(1c)), estimated glomerular filtration rate.
Mean diabetes duration was 14.6 +/- 10.6 years. Albuminuria was present in 46% of participants. In individuals with diabetes duration of 11 to 15 years, 25% had microalbuminuria and 18.2% had macroalbuminuria. Despite a positive family history and a high prevalence of albuminuria, only 35.3% of participants had a target systolic BP less than 130 mm Hg. HbA(1c) levels were 7% or greater in 57.4% of patients, and 26.4% of participants were smokers. Only 58% of patients received angiotensin-converting enzyme inhibitors or receptor blockers. In microalbuminuric participants, HbA(1c) level was greater than 10% in 28.6% versus 13.3% in those without albuminuria (P = 0.02).
A control group of diabetic siblings without a family history of diabetic kidney disease was not obtained.
Diabetic siblings of patients with diabetic kidney disease have a high prevalence of albuminuria and poor glycemic and BP control. Targeting these high-risk individuals for interventions to improve their BP and blood glucose control might prevent or slow the progression of diabetic kidney disease.
糖尿病肾病所致肾衰竭患者的糖尿病同胞未来发生肾衰竭的风险增加5倍。本研究的目的是确定糖尿病肾病患者的糖尿病同胞中肾病的危险因素、临床特征及治疗模式。
采用从糖尿病肾病患者的糖尿病同胞中收集的数据进行横断面分析。
来自俄亥俄州克利夫兰市或北卡罗来纳州温斯顿 - 塞勒姆市半径400英里范围内的295名糖尿病同胞,平均糖尿病病程为15年。
人口统计学数据、糖尿病病程、血压(BP)、医疗保健可及性和糖尿病控制情况。
蛋白尿(定义为尿白蛋白 - 肌酐比值≥30 mg/g,其中微量蛋白尿为白蛋白30至300 mg/g,大量蛋白尿为白蛋白>300 mg/g)、肾功能。
血压、尿白蛋白 - 肌酐比值、血清肌酐、糖化血红蛋白(HbA1c)、估计肾小球滤过率。
平均糖尿病病程为14.6±10.6年。46%的参与者存在蛋白尿。在糖尿病病程为11至15年的个体中,25%有微量蛋白尿,18.2%有大量蛋白尿。尽管有家族病史且蛋白尿患病率高,但只有35.3%的参与者目标收缩压低于130 mmHg。57.4%的患者糖化血红蛋白水平≥7%,26.4%的参与者吸烟。只有58%的患者接受了血管紧张素转换酶抑制剂或受体阻滞剂治疗。在微量蛋白尿参与者中,28.6%的糖化血红蛋白水平>10%,而无蛋白尿者为13.3%(P = 0.02)。
未获得无糖尿病肾病家族史的糖尿病同胞对照组。
糖尿病肾病患者的糖尿病同胞蛋白尿患病率高,血糖和血压控制不佳。针对这些高危个体进行干预以改善其血压和血糖控制,可能预防或延缓糖尿病肾病的进展。